As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 4,158 4,158 |
4%
4%
|
|
| Gross Profit | 3,679 3,679 |
3%
3%
|
|
| EBITDA | 1,098 1,098 |
17%
17%
|
|
| EBIT (Operating Income) EBIT | 454 454 |
36%
36%
|
|
| Net Profit | -368 -368 |
180%
180%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
| Head office | Ireland |
| CEO | Bruce Cozadd |
| Employees | 2,800 |
| Founded | 2005 |
| Website | www.jazzpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


